Proprietary & ConfidentialThis material is proprietary to My Life Spark P.C. Unauthorized use, reproduction, or distribution is strictly prohibited.

Blog··8 min read

Trastuzumab and HER2 Therapy: Cardiac Monitoring That Continues After the Infusion Stops

Trastuzumab-related cardiac dysfunction is often reversible in active therapy — and often forgotten in survivorship. A practical monitoring cadence for the years after HER2-directed treatment ends.

Trastuzumab-related cardiac dysfunction is the textbook example of a cardio-oncology story that is well managed during active therapy and quietly forgotten in survivorship. For most patients the dysfunction is reversible; for a real minority it persists or emerges later. This is a practical survivorship monitoring cadence for the years after HER2-directed treatment ends.

What actually happens on therapy

Trastuzumab causes reversible myocardial dysfunction in a meaningful minority of patients — the reported incidence range for asymptomatic LVEF decline is roughly 4–20%, with symptomatic heart failure in the low single digits. Prior anthracycline exposure, older age, hypertension, and baseline low-normal LVEF are the recognized risk multipliers. Dose is not the driver the way it is for anthracyclines.

The on-therapy monitoring pattern (context)

Baseline LVEF (echo or MUGA), then LVEF every 3 months during therapy, with hold-and-reassess thresholds at absolute LVEF < 50% or a decline of ≥ 10 percentage points from baseline. This is the reference schedule everyone in oncology knows. The gap is what happens after therapy ends.

Survivorship monitoring: the schedule most patients need

For patients with no on-therapy events and no anthracycline co-exposure: an echo at 6–12 months post-completion is reasonable, and if normal, spacing to every 3–5 years thereafter — with a low threshold to re-image for new symptoms.

For patients with any on-therapy LVEF drop (even if it recovered), documented symptomatic event, or anthracycline co-exposure: echo at 6 months post-completion, then annually for 2–3 years, then every 2–3 years indefinitely.

Global longitudinal strain, where available, is the most useful sensitivity signal in the preserved-LVEF group — a GLS worse than baseline by ≥ 15% warrants cardio-oncology consultation even with a normal LVEF number.

What to modify beyond the imaging cadence

Hypertension control (target < 130/80), LDL to ASCVD-risk-appropriate targets, glucose, and tobacco cessation. These are the primary-care levers that meaningfully change the trajectory. Continuing an ACE-I/ARB and beta-blocker that were started during on-therapy dysfunction is a common survivorship decision — do not stop them silently at a routine visit.

Escalation triggers

New dyspnea on exertion, resting tachycardia, orthopnea, unexplained weight gain, or a fall in exercise tolerance in a survivor with prior HER2-directed therapy warrants an echo within 2 weeks and cardio-oncology consultation. Do not wait for the surveillance interval.

The hand-off problem

The most common failure mode is not the wrong interval — it is that no one owns the interval. A survivor moves out of oncology follow-up, the primary-care physician does not know the on-therapy history, and the next echo happens only when symptoms are already present. A patient-owned transition-of-care plan carrying the exposure, on-therapy event history, and the next surveillance date closes that gap in a single line.

Frequently asked questions

Do I need to continue an ACE-I or beta-blocker after HER2 therapy ends if LVEF recovered?
Often yes, particularly if they were started for an on-therapy dysfunction event. Decisions to discontinue should be made in coordination with cardio-oncology, not silently at a routine visit.
Is MUGA acceptable instead of echo in survivorship?
It is acceptable for LVEF tracking but does not provide strain data. Echo with GLS is preferred where available, particularly for lower-risk long-term survivors who want to minimize cumulative radiation exposure.
How does anthracycline co-exposure change things?
It shifts the survivor into the higher-risk group. The interval becomes closer to the anthracycline cardiomyopathy cadence — annual for the first 2–3 years post-therapy, then every 2–3 years indefinitely.
What about newer HER2 conjugates (T-DM1, T-DXd)?
Cardiac signal is generally lower than trastuzumab alone but not zero. Follow the same on-therapy monitoring pattern, and in survivorship default to the anthracycline-co-exposure schedule if the patient received any anthracycline in the treatment course.
Back to top